[go: up one dir, main page]

ZA200908089B - Induction of tolerogenic phenotype in mature dendritic cells - Google Patents

Induction of tolerogenic phenotype in mature dendritic cells

Info

Publication number
ZA200908089B
ZA200908089B ZA200908089A ZA200908089A ZA200908089B ZA 200908089 B ZA200908089 B ZA 200908089B ZA 200908089 A ZA200908089 A ZA 200908089A ZA 200908089 A ZA200908089 A ZA 200908089A ZA 200908089 B ZA200908089 B ZA 200908089B
Authority
ZA
South Africa
Prior art keywords
induction
dendritic cells
mature dendritic
tolerogenic phenotype
tolerogenic
Prior art date
Application number
ZA200908089A
Other languages
English (en)
Inventor
Herrera Jose M Carballido
Vries Jan E De
Ulf Korthaeuer
Maria Grazia Roncarolo
Sylvia Adriana Gregori
Original Assignee
Novartis Ag
San Raffaele Centro Fond
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, San Raffaele Centro Fond filed Critical Novartis Ag
Publication of ZA200908089B publication Critical patent/ZA200908089B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ZA200908089A 2007-06-05 2009-11-17 Induction of tolerogenic phenotype in mature dendritic cells ZA200908089B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07109672 2007-06-05

Publications (1)

Publication Number Publication Date
ZA200908089B true ZA200908089B (en) 2010-07-28

Family

ID=39721982

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200908089A ZA200908089B (en) 2007-06-05 2009-11-17 Induction of tolerogenic phenotype in mature dendritic cells

Country Status (17)

Country Link
US (1) US20100183602A1 (xx)
EP (1) EP2160410A1 (xx)
JP (1) JP2010529078A (xx)
KR (1) KR20100035643A (xx)
CN (1) CN101687928A (xx)
AU (1) AU2008258646A1 (xx)
BR (1) BRPI0812205A2 (xx)
CA (1) CA2689570A1 (xx)
CL (1) CL2008001620A1 (xx)
EA (1) EA200901621A1 (xx)
IL (1) IL202230A0 (xx)
MA (1) MA31667B1 (xx)
MX (1) MX2009013220A (xx)
TN (1) TN2009000494A1 (xx)
TW (1) TW200907061A (xx)
WO (1) WO2008148761A1 (xx)
ZA (1) ZA200908089B (xx)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007070660A2 (en) 2005-12-13 2007-06-21 President And Fellows Of Harvard College Scaffolds for cell transplantation
WO2009002401A2 (en) 2007-06-21 2008-12-31 President And Fellows Of Harvard College Scaffolds for cell collection or elimination
WO2009102465A2 (en) 2008-02-13 2009-08-20 President And Fellows Of Harvard College Continuous cell programming devices
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
EP2461828B1 (en) * 2009-07-31 2017-06-21 President and Fellows of Harvard College Programming of cells for tolerogenic therapies
EP2305277A1 (en) * 2009-09-18 2011-04-06 Forskarpatent I Syd AB Use of tolerogenic dendritic cells in treatment and prevention of atherosclerosis
SI2624873T1 (sl) 2010-10-06 2020-07-31 President And Fellows Of Harvard College Injektabilni, pore-formirajoči hidrogeli za celične terapije - na osnovi materialov
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
ES2685327T3 (es) 2011-04-28 2018-10-08 President And Fellows Of Harvard College Armazones tridimensionales macroscópicos preformados inyectables para administración mínimamente invasiva
EA201790045A1 (ru) 2011-04-29 2017-09-29 Селекта Байосайенсиз, Инк. Наноносители, вырабатывающие имунную толерантность, для антиген-специфического удаления т-эффекторных клеток
WO2012167230A1 (en) 2011-06-03 2012-12-06 President And Fellows Of Harvard College In situ antigen-generating cancer vaccine
WO2013036299A1 (en) * 2011-09-06 2013-03-14 Selecta Biosciences, Inc. Transplantable graft-specific induced tolerogenic dendritic cells and methods of use
ES2773895T3 (es) 2012-04-16 2020-07-15 Harvard College Composiciones de sílice mesoporosa para modular las respuestas inmunitarias
EP2991631A4 (en) 2013-05-03 2016-11-16 Selecta Biosciences Inc TOLEROGENIC SYNTHETIC NANOTRANS AND THERAPEUTIC MACROMOLECULES FOR REDUCED OR IMPROVED PHARMACODYNAMIC EFFECTS
EP3137105A4 (en) 2014-04-30 2017-12-27 President and Fellows of Harvard College Combination vaccine devices and methods of killing cancer cells
BR112017001311A2 (pt) 2014-09-07 2017-11-14 Selecta Biosciences Inc métodos e composições para atenuar as respostas imunes do vetor de transferência anti-viral de salto de éxon
HK1247861A1 (zh) 2015-01-30 2018-10-05 President And Fellows Of Harvard College 用於癌症治疗的肿瘤周围和肿瘤内部材料
CN114099793A (zh) 2015-04-10 2022-03-01 哈佛学院院长等 免疫细胞捕获装置及其制备和使用方法
WO2017136837A1 (en) 2016-02-06 2017-08-10 President And Fellows Of Harvard College Recapitulating the hematopoietic niche to reconstitute immunity
EP4606890A3 (en) 2016-07-13 2025-12-03 President and Fellows of Harvard College Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
KR102638898B1 (ko) 2016-08-02 2024-02-22 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 면역 반응을 조정하기 위한 생체재료
AU2018236123B2 (en) 2017-03-11 2024-04-18 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
CA3100349A1 (en) * 2018-05-17 2019-11-21 The Board Of Trustees Of The Leland Stanford Junior University Receptor inhibition by phosphatase recruitment
WO2020061129A1 (en) 2018-09-19 2020-03-26 President And Fellows Of Harvard College Compositions and methods for labeling and modulation of cells in vitro and in vivo
EP4034148A4 (en) 2019-09-23 2025-09-10 Harvard College BIOMATERIAL-BASED ANTIGEN-FREE VACCINE AND ITS USE

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0103389D0 (en) * 2001-02-12 2001-03-28 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
TW200907061A (en) 2009-02-16
MX2009013220A (es) 2010-04-09
AU2008258646A1 (en) 2008-12-11
CN101687928A (zh) 2010-03-31
KR20100035643A (ko) 2010-04-05
US20100183602A1 (en) 2010-07-22
CL2008001620A1 (es) 2009-02-20
EP2160410A1 (en) 2010-03-10
CA2689570A1 (en) 2008-12-11
BRPI0812205A2 (pt) 2014-11-25
TN2009000494A1 (en) 2011-03-31
WO2008148761A1 (en) 2008-12-11
EA200901621A1 (ru) 2010-06-30
IL202230A0 (en) 2010-06-16
MA31667B1 (fr) 2010-09-01
JP2010529078A (ja) 2010-08-26

Similar Documents

Publication Publication Date Title
IL202230A0 (en) Induction of tolerogenic phenotype in mature dendritic cells
IL301475B1 (en) Laboratory methods for increasing the vitality of immune system cells
IL217552A0 (en) Methods and compositions for in vitro and in vivo chondrogenesis
IL213637A0 (en) Sustained release of nutrients in vivo
AU326555S (en) Battery charger
EP2243939A4 (en) TURBO
EP2305164A4 (en) DENTAL LOAD DISPENSER
EP2497769A4 (en) PYRROLOCHINOLINCHINONE IN FREE FORM
GB201013443D0 (en) Compositions and methods for producing dendritic cells
EP2227540A4 (en) DIFFERENTIATION OF HUMAN CELLS
GB0802154D0 (en) Improvements in electrical means
IL208579A0 (en) Methods and use of inducing a poptosis in cancer cells
IL221504B (en) Compositions and methods for targeting type 1 interferon producing cells
GB0912437D0 (en) Improvements in and relating to chair lifts
PL2307448T3 (pl) Wytwarzanie polilizyny i poliornityny o małym ciężarze cząsteczkowym z wysoką wydajnością
ZA201201369B (en) Improvements in and relating to cable-barriers
GB2450466B (en) Improvements in and relating to electric plugs
HK1141305A (en) Induction of tolerogenic phenotype in mature dendritic cells
GB2458569B (en) Improvements in and relating to cloches
GB0914448D0 (en) Improvements in pelvic support
GB0725303D0 (en) Improvement in the structure of an electrical receptacle
GB0807845D0 (en) Improvements in and relating to telecommunications
GB0904880D0 (en) Gravity power renewed
GB201005441D0 (en) Improvements in wheelchairs
GB0822250D0 (en) Improvements in and relating to karabiners